A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505775-70-00

Acronym

EMN34

Enrollment

105

Registered

2024-02-13

Start date

2024-04-08

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High risk smoldering multiple myeloma

Brief summary

Complete remission rate at the end of cycle 6, assessed by International Myeloma Working Group [IMWG] criteria., Rate of grade >3-4 non hematologic adverse events, assessed according to CTCAE 5.0.

Interventions

DRUGPARACETAMOL

DRUGELRANATAMAB

DRUGDIPHENHYDRAMINE HYDROCHLORIDE

DRUGDEXAMETHASONE

DRUGRoActemra 20 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Complete remission rate at the end of cycle 6, assessed by International Myeloma Working Group [IMWG] criteria., Rate of grade >3-4 non hematologic adverse events, assessed according to CTCAE 5.0.	—

Countries

Finland, France, Greece, Italy, Netherlands, Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026